Teva Pharmaceutical Industries Limited (TEVA) and Lundbeck Inc. Release: TEMPO Extension Study Further Demonstrates the Benefits of Azilect(R) in Early Parkinson's Disease Patients
8/5/2010 10:49:12 AM
JERUSALEM & VALBY, Denmark--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and H. Lundbeck A/S (Lundbeck) today announced newly published long-term data on Azilect® (rasagiline tablets) from the TEMPO study and its open-label extension. The findings confirm the long-term efficacy, safety and tolerability of Azilect® in patients with Parkinson’s disease (PD) and further demonstrate the benefits obtained with early treatment initiation. The data was published in the June 2010 issue of the International Journal of Neuroscience.